2026-06-14T03:52:30Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/187832024-09-21T19:38:09Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16968

00925njm 22002777a 4500 dc Rueda Domínguez, Antonio author Cirauqui, Beatriz author García Castaño, Almudena author Alvarez Cabellos, Ruth author Carral Maseda, Alberto author Castelo Fernández, Beatriz author Iglesias Rey, Leticia author Rubió-Casadevall, Jordi author Arrazubi, Virginia author Mesía, Ricard author 2022-03-18 Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time. 10.1007/s12094-022-02814-x 1699-3055 Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico http://hdl.handle.net/10668/21108 35303267 http://hdl.handle.net/20.500.12105/18783 Clinical Practice Guidelines Diagnosis Follow-up Nasopharyngeal cancer Treatment SEOM-TTCC clinical guideline in nasopharynx cancer (2021).